Trials / Conditions / MGMT-Unmethylated Glioblastoma

MGMT-Unmethylated Glioblastoma

15 registered clinical trials studyying MGMT-Unmethylated Glioblastoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Dia NCT07452458	NRG Oncology	Phase 3
Recruiting	Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Gliobla NCT06991101	Baptist Health South Florida	Phase 2
Recruiting	DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma NCT06504381	University of California, San Francisco	Phase 1 / Phase 2
Recruiting	WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma NCT05879250	Northwestern University	Phase 2
Recruiting	Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells NCT06186401	Hideho Okada, MD, PhD	Phase 1
Recruiting	Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases NCT05909618	Sheba Medical Center	Phase 2
Unknown	Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma NCT05694416	Zhongnan Hospital	Phase 2
Active Not Recruiting	Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma NCT05236036	Northwestern University	Phase 1
Unknown	Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblast NCT05033587	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 2
Unknown	Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma NCT04725214	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Completed	Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usu NCT04396860	National Cancer Institute (NCI)	Phase 2 / Phase 3
Unknown	Repurposing Chlorpromazine in the Treatment of Glioblastoma NCT04224441	Marco G Paggi, MD, PhD	Phase 2
Completed	Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated G NCT03452930	M.D. Anderson Cancer Center	Phase 1
Terminated	Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer NCT03107780	National Cancer Institute (NCI)	Phase 1
Terminated	Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblast NCT03250299	Basilea Pharmaceutica	Phase 1